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For a very long time, the de novo development of 
paraproteinemia has been observed after allogenic stem 
cell transplantation (allo-HSCT) of non-myeloma pa-
tients and even in patients with solid organ transplanta-
tions [1, 2]. Its appearance is likely linked to the profound 
immunodeficiency that these patients experience, but 
the causal trigger and clinical impact remain poorly un-
derstood. Earlier studies described the association of 
paraproteinemia in patients with allo-HSCT with an 
alemtuzumab-based conditioning regimen and cyto-
megalovirus (CMV) reactivation [3]. However, even af-
ter the emergence of other conditioning regimens and 
the following reduction of the use of alemtuzumab over 
the past decades, paraproteinemia remained a continu-
ously observed phenomenon after allo-HSCT. Newer 
studies suggest that the process of immunological recon-
stitution of the individual patient itself with an altered 
B-cell homeostasis might lead to a selected production of 
immunoglobulins [4, 5]. 
The fact that it can be easily monitored in the periph-
eral blood makes paraproteinemia a very promising tar-
get for research and the clinical and prognostic impact of 
this biomarker needs further investigation. The report by 
Iovino et al. [6] in this issue of Acta Haematolgica is a rep-
lication study probing this phenomenon. Their results are 
in line with another study recently published by our 
group [5] and confirmed a prognostic relevance. The sta-
tistical analysis of 194 patients revealed a better outcome 
in patients with paraproteinemia in the first year after al-
lo-HSCT and this trend was also visible for the 5-year 
overall survival. Furthermore, there was no evidence of 
an association of paraproteinemia with the conditioning 
regimen or with infectious conditions such as CMV reac-
tivation. Other clinical parameters such as graft versus 
host disease or underlying diseases were also not signifi-
cantly connected; however, the small size of subgroups 
needs to be considered. It remains to be investigated 
though which immune system reconstitutions will re-
spond with a paraprotein production and therefore pro-
vide an improved outcome in the first year after allo-
HSCT. The overall incidence of paraproteinemia in the 
study by Iovino et al. [6] was low and, accordingly, the 
statistical power was not high enough to make a state-
ment about predicting factors for a paraproteinemia. The 
authors themselves indicated that due to the already ob-
served transient nature of the paraproteinemia, they 
might have missed short-lasting appearances of parapro-
teins. A profound immunodeficiency is expected to be 
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prevalent for at least 3 months after transplantation and 
it would be interesting to investigate the development of 
paraproteinemia within these first 3 months. According-
ly, I would encourage screening for paraproteinemia 
from the beginning, possibly with shorter intervals to im-
prove understanding of its kinetics and development. The 
fact that the appearance of paraproteinemia mostly oc-
curs within the first year after allo-HSCT might hint to 
the kinetics of B-cell reconstitution.
Even though there are more and more patients eligible 
for allogenic transplantation, there are very limited data 
on this topic. While paraproteinemia after allo-HSCT is 
mostly transient and does not translate into the develop-
ment of plasma cell myeloma or lymphoma, further un-
derstanding of its cause and impact on the disease course 
of the patient is of high prognostic interest. The study by 
Iovino et al. [6] provides another piece to the puzzle and 
helps to consolidate the benign character of this parapro-
teinemia. Even though their sample size was rather low, 
the importance of such studies should not be underesti-
mated as they lay the foundation for subsequent meta-
analyses that might then be able to make statements of 
high clinical and statistical significance.
Furthermore, it raises interest to gain more insight 
into this particular immune reconstitution, even perhaps 
leading to an overall better understanding of the develop-
ment of monoclonal gammopathies in general and, ad-
ditionally, might yield an easily assessable prognostic fac-
tor for patients after allo-HSCT. 
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